## **PROXY FORM**

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Calliditas Therapeutics AB (publ), Reg. No. 56659-9766, at the annual general meeting of Calliditas Therapeutics AB (publ) on 25 June 2020.

## Proxy

Name of the proxy	Personal identity number/Date of birth
Address	
Postal code and city	Telephone number

## Signature by the shareholder

Name of the shareholder	Personal identity number/Date of birth/Registration number
Place and date	Telephone number
Signature*	

\*If signing for a company, a clarification of signature shall be included above and an up-to-date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance - as set out in the notice convening the meeting - even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form in original (with any enclosures) should be sent to Calliditas Therapeutics, "General meeting", PO Box 703 51, SE-107 24 Stockholm, Sweden, together with the notice of attendance. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be sent to the company.

## Processing of personal data

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.